Preface vii

List of Contributors ix

Other Volumes in the Series xxxix

Chapter 1. Why choose mammalian cells for protein production?

Savvas C. Makrides and Holly L. Prentice 1

Abbreviations 6

References 6

Chapter 2. Vectors for gene expression in mammalian cells

Savvas C. Makrides 9

1\. Introduction 9

2\. Transient gene expression 9

3\. Stable gene expression 14

4\. Genetic elements of mammalian expression vectors 15

4.1. Transcriptional control elements 17

4.2. Translational control elements 20

5\. Selectable markers 21

6\. Signal peptides and fusion moieties 21

7\. mRNA and protein stability 22

8\. Coordinated expression of multiple genes 23

Abbreviations 24

References 25

Chapter 3.1. Virus-based vectors for gene expression in mammalian cells: Herpes simplex virus

Edward A. Burton, Qing Bai, William F. Goins, David Fink and Joseph C. Glorioso 27

1\. Introduction 27

2\. Herpes Simplex Virus--relevant basic biology 27

2.1. Structure of HSV-1 28

2.2. Mechanisms of HSV-1 cell entry 29

2.3. Regulation of viral genes during lytic infection 30

2.4. The viral life cycle in vivo 31

2.5. Regulation of latency and the latency-associated transcripts 32

3\. Using HSV-1 to make gene therapy vectors 33

3.1. Advantages of HSV as a vector 33

3.2. Eliminating viral replication 34

3.2.1. Conditionally replicating vectors 34

3.2.2. Replication-defective vectors 34

3.2.3. Amplicons 36

3.3. Minimising toxicity from replication-defective vectors 36

3.4. Inserting transgenes into replication-defective vectors 37

3.5. Vector targeting 38

3.5.1. Targeted adsorption 38

3.5.2. Targeted entry 40

3.5.3. Pseudotyping HSV using surface determinants from another virus 40

3.6. Use of latency promoters to drive transgene expression 41

3.7. Vector production 41

4\. Applications of HSV vectors in the nervous system 42

4.1. The peripheral nervous system 42

4.2. The central nervous system 45

4.3. Malignant glioma 47

5\. Applications outside the nervous system 48

5.1. Skeletal muscle 48

5.2. Stem cells 49

5.3. Arthritis and secreted proteins 50

6\. Conclusions 50

Abbreviations 51

References 51

Chapter 3.2. Virus-based vectors for gene expression in mammalian cells: Epstein-Barr virus

Gregory Kennedy and Bill Sugden 55

1\. Introduction 55

2\. Replication of the EBV genome 55

2.1. Replication during the latent phase of EBV\'s life cycle 55

2.2. Replication during the lytic phase of EBV\'s life cycle 58

3\. EBV-based vectors for gene expression in cell culture 58

4\. EBV-based vectors for gene therapy 60

4.1. Replication-competent vectors 60

4.2. Replication-deficient vectors 62

4.3. Vectors that accommodate large inserts for gene therapy 63

5\. Cell-specific gene expression 64

6\. A case study for the future 66

7\. Conclusions 67

Abbreviations 68

References 68

Chapter 3.3. Virus-based vectors for gene expression in mammalian cells: SV40

David S. Strayer, Pierre Cordelier, Julien Landré, Alexei Matskevitch, Hayley J. McKee, Carmen N. Nichols, Martyn K. White and Marlene S. Strayer 71

Abstract 71

1\. Introduction 71

2\. The biology of wild type SV40 73

2.1. WtSV40 genome organization 73

2.2. Host range and cell entry 73

2.3. Tag 73

2.4. Persistence of wtSV40 75

2.5. Immunogenicity 75

2.6. Virus replication 75

3\. Making recombinant SV40 viruses and using them for gene delivery 76

3.1. Producing rSV40 vectors 76

3.2. Transgene expression 76

3.3. Manipulating rSV40 vectors 79

3.4. Transduction efficiency and persistence of transgene expression 79

3.5. Immunogenicity 80

3.6. Uses of rSV40 gene delivery vectors 81

3.6.1. Delivering in vitro transgenes encoding intracellular proteins 81

3.6.2. Studies in vitro with transgenes encoding untranslated RNAs 81

3.6.3. Work done in vitro to deliver proteins that are secreted 83

3.6.4. Immunizing against foreign antigens in vivo 83

3.6.5. Studies performed in vivo to rectify an inherited or acquired defect 83

3.7. Safety 84

3.7.1. Recombination in packaging 84

3.7.2. Insertional mutation 85

3.8. Limitations 86

3.8.1. Physical constraints 86

3.8.2. Restrictions in effective expression of certain transgenes 87

3.8.3. Appropriateness for certain applications 87

4\. Conclusions and future perspectives 87

Abbreviations 89

References 90

Chapter 3.4. Virus-based vectors for gene expression in mammalian cells: Adeno-associated virus

Xiao Xiao 93

1\. Biology of adeno-associated virus 93

2\. Production of recombinant AAV vectors 97

3\. In vitro and in vivo gene transfer 99

4\. Immunological aspects of AAV vectors 102

5\. Development of new AAV vectors 103

Abbreviations 105

References 106

Chapter 3.5. Virus-based vectors for gene expression in mammalian cells: Adenovirus

Denis Bourbeau, Yué Zeng and Bernard Massie 109

1\. Introduction 109

2\. Adenoviral vectors 111

2.1. First generation AdV 111

2.2. Second generation AdV 112

2.3. Third generation AdV 113

2.4. Replicative AdV 114

3\. Gene delivery 115

3.1. Cell entry pathway 115

3.1.1. Ad capsid proteins involved in virus entry 115

3.1.2. Cell receptors 115

3.1.3. Mechanisms of early steps of cell infection by Ad 116

3.2. Targeting of AdV 116

3.2.1. Conjugate targeting system 118

3.2.2. Genetic targeting system 118

4\. Gene expression 119

4.1. High-level expression 119

4.2. Specific transgene expression 120

4.2.1. Tissue-specific promoters 120

4.2.2. Tumor-specific promoters 120

5\. Production and analyses of viral particles 121

6\. Conclusion 122

Abbreviations 122

References 123

Chapter 3.6. Virus-based vectors for gene expression in mammalian cells: Vaccinia virus

Miles W. Carroll and Gerald R. Kovacs 125

1\. Introduction 125

2\. Vaccinia virus molecular biology 125

2.1. Vaccinia virus promoters 126

3\. Construction of recombinant poxvirus vectors 127

4\. Chimeric VV-bacteriophage expression vectors 130

5\. Improved safety of VV vectors 130

6\. Non-vaccinia poxvirus vectors 132

7\. Laboratory and clinical applications 132

Abbreviations 134

References 134

Chapter 3.7. Virus-based vectors for gene expression in mammalian cells: Baculovirus

J. Patrick Condreay and Thomas A. Kost 137

1\. Introduction 137

2\. Baculoviruses as insect cell expression vectors 137

3\. Molecular biology of virus vector construction 139

4\. Baculoviruses as mammalian cell expression vectors 139

5\. Characteristics of baculovirus-mediated mammalian gene delivery 142

6\. Applications of the baculovirus mammalian gene delivery vector 145

7\. Points to consider 146

Abbreviations 148

References 148

Chapter 3.8. Virus-based vectors for gene expression in mammalian cells: Coronavirus

Luis Enjuanes, Fernando Almazán and Javier Ortego 151

1\. Introduction 151

2\. Coronavirus pathogenicity 152

3\. Molecular biology of coronavirus 153

3.1. Coronavirus genome 153

3.2. Coronavirus proteins 154

4\. Helper-dependent expression systems 154

4.1. Group 1 coronaviruses 154

4.2. Group 2 coronaviruses 155

4.3. Group 3 coronaviruses 155

4.4. Heterologous gene expression levels in helper-dependent expression systems 155

5\. Single genome coronavirus vectors 156

5.1. Group 1 coronaviruses 156

5.2. Group 2 coronaviruses 159

5.3. Group 3 coronaviruses 160

5.4. Replication-competent propagation-deficient coronavirus-derived expression systems 161

5.5. Cloning capacity of coronavirus expression vectors 162

6\. Optimization of transcription levels 162

6.1. Characteristics of the TRS 163

6.2. Effect of CS copy number on transcription 164

7\. Modification of coronavirus tropism and virulence 164

8\. Expression systems based on arteriviruses 164

9\. Conclusions 165

Abbreviations 165

References 166

Chapter 3.9. Virus-based vectors for gene expression in mammalian cells: Poliovirus

Shane Crotty and Raul Andino 169

1\. Introduction 169

2\. A poliovirus vector-based HIV vaccine 169

2.1. Rationale for using poliovirus as a live virus vector for an HIV-1 vaccine 170

2.1.1. AIDS: a sexually transmitted disease 171

2.1.2. Criteria for a mucosal HIV vaccine 172

2.1.3. The mucosal immune system and vaccine development 173

2.1.4. Live-attenuated Sabin poliovirus as AIDS vaccine vector 174

2.1.5. Use of poliovirus vectors in developing countries 174

2.2. Poliovirus and vaccine strains: human clinical experience 174

2.2.1. Poliovirus vaccines 174

2.2.2. Advantages of oral poliovirus vaccine 175

2.2.3. Physical stability of poliovirus vaccine 175

2.2.4. Reversion of OPV to neurovirulent forms 175

3\. Poliovirus vector development and its immunogenic potential 176

3.1. Poliovirus-derived vaccine vectors 176

3.2. Other poliovirus and picornavirus vector strategies 177

3.3. Restriction of the poliovirus vectors 178

3.4. Prime-boost approach using different poliovirus serotypes 178

3.5. Testing the immunogenic capacity of poliovirus vaccine vectors 178

3.5.1. Poliovirus vectors induce CTL responses 178

3.5.2. Pre-existing immunity to poliovirus vectors 179

3.6. Immunogenic potential of poliovirus vectors 180

3.7. Induction of protective immunity against a challenge with pathogenic SIV~mac~251 180

3.7.1. Intranasal immunization-induced serum antibody responses 180

3.7.2. Intranasal immunization-induced rectal and vaginal anti-SIV antibody responses 181

3.7.3. Intranasal immunization-induced CTL responses 181

3.7.4. Protection from challenge with pathogenic SIV~mac~251 181

3.7.5. Using a library of defined SIV antigens expressed by Sabin vectors 183

3.8. Immunological complexity and antigen dilution 184

3.9. Poliovirus eradication and vaccine vectors 184

Abbreviations 185

References 185

Chapter 3.10. Virus-based vectors for gene expression in mammalian cells: Sindbis virus

Henry V. Huang and Sondra Schlesinger 189

1\. Introduction 189

2\. Viral genetic elements 190

2.1. Nonstructural proteins 190

2.2. Structural proteins 191

2.3. Cis-acting signals 191

2.3.1. Replication signals 191

2.3.2. Subgenomic mRNA promoter 192

2.3.3. Translation-enhancing signal 192

2.3.4. Packaging signal 192

3\. Packaging of replicons 192

4\. Effects of alphaviruses and replicons on infected cells 193

5\. Expression in neurons 194

6\. Insect and crustacea 195

6.1. Interrupting mosquito transmission of pathogens 196

6.2. Inhibiting gene expression and ectopic gene expression in arthropods 197

7\. Vaccines for infectious diseases and cancer 198

7.1. Replicon particles targeting to dendritic cells 199

7.2. Vaccination studies in mice and guinea pigs 200

7.2.1. Replicon particles 200

7.2.2. Nucleic acids 201

7.3. Vaccination studies in primates 201

7.4. Immunotherapy and targeted treatment against tumors 202

8\. Perspectives 202

Abbreviations 203

References 203

Chapter 3.11. Virus-based vectors for gene expression in mammalian cells: Semliki Forest virus

Kenneth Lundstrom 207

1\. Introduction 207

2\. Expression of topologically different proteins 209

2.1. Intracellular proteins 209

2.2. Membrane proteins and receptors 210

2.3. Secreted proteins 212

3\. Host cell range 212

3.1. Mammalian host cell lines 212

3.2. Non-mammalian cells 214

4\. Scale-up of protein production 215

4.1. Drug screening 215

4.2. Structural biology 215

5\. Expression in primary cell cultures 216

5.1. Fibroblasts 216

5.2. Neurons 216

5.3. Other cell types 217

6\. Expression in hippocampal slice cultures 217

6.1. Expression in neurons 217

6.2. Co-expression of GFP 218

7\. SFV vectors in vivo 219

7.1. Vaccine production 219

7.2. Stereotactic injections 219

8\. Safety of SFV vectors 219

9\. SFV vectors in gene therapy 220

9.1. Intratumoral injections 220

9.2. Systemic delivery 221

9.3. Targeting 221

10\. SFV vectors as tools for virus assembly 221

11\. Modifications of SFV vectors 222

11.1. Non-cytopathogenic vectors 222

11.2. Temperature-sensitive mutations 223

11.3. Down-regulated expression 224

12\. Novel technologies 224

12.1. Inducible stable expression vectors 224

12.2. Antisense and ribozyme applications 224

12.3. RNA interference 225

13\. Conclusions 225

Abbreviations 226

References 227

Chapter 3.12. Virus-based vectors for gene expression in mammalian cells: Retrovirus

Cristina Parolin and Giorgio Palù--- 231

1\. Introduction 231

2\. Biology of retroviruses 231

2.1. Virion morphology 231

2.2. Genomic organization 232

2.3. The life cycle 234

3\. Development of recombinant retrovirus vectors 235

3.1. Replication-competent vectors 235

3.1.1. Avian retroviruses 235

3.1.2. Other retroviruses 237

3.2. Replication-defective vectors 237

3.2.1. The packaging system 239

3.2.2. The vector 241

4\. Expression of the transgene 242

4.1. Basic design 242

4.2. Self-inactivating vectors 244

5\. Targeting 245

5.1. Transcriptional targeting 245

5.2. Cellular targeting 246

6\. Conclusion and perspectives 247

Abbreviations 247

References 248

Chapter 3.13. Virus-based vectors for gene expression in mammalian cells: Lentiviruses

Mehdi Gasmi and Flossie Wong-Staal 251

1\. Introduction 251

2\. Genetic structure and biology of lentiviruses 251

2.1. Genome, structural proteins and enzymes 252

2.2. Regulatory and accessory proteins 253

2.3. Redundancy of viral determinants of nuclear import 254

3\. HIV-1-derived vector packaging system 255

3.1. Packaging construct 255

3.2. Transfer vector 256

3.3. Requirement for Rev and the RRE 257

3.4. Requirement for accessory proteins 258

4\. Lentiviral vector production 258

5\. Pseudotyped vectors 259

6\. Expression from lentiviral vectors 260

6.1. Promoters 260

6.2. Enhancers of gene expression 261

6.3. Gene silencing 261

6.4. Regulation of gene expression 261

7\. Gene transfer applications 262

8\. Conclusion 262

Abbreviations 262

References 263

Chapter 4. Methods for DNA introduction into mammalian cells

Pamela A. Norton and Catherine J. Pachuk 265

1\. Introduction 265

2\. Barriers to successful transfection 266

2.1. DNA condensation 266

2.2. DNA uptake by cells 267

2.3. Nuclear entry 268

3\. Comparison of available methods 269

3.1. Polycation-mediated DNA uptake 270

3.2. Calcium phosphate-mediated DNA uptake 271

3.3. Lipid-mediated DNA uptake 271

3.4. Electroporation and other physical methods 272

3.5. Biologically vectored approaches 273

4\. Applications 274

Abbreviations 275

References 276

Chapter 5. Lipid reagents for DNA transfer into mammalian cells

Christophe Masson, Virginie Escriou, Michel Bessodes and Daniel Scherman 279

1\. Introduction 279

2\. General structure of cationic lipids 279

3\. Formulation and physicochemical properties 280

4\. Mechanisms of in vitro transfection 282

5\. In vivo administration 284

6\. Targeting 285

7\. New strategies to improve in vivo transfection 286

8\. Conclusion 286

Abbreviations 287

References 287

Chapter 6. Reporter genes for monitoring gene expression in mammalian cells

Jawed Alam and Julia L. Cook 291

1\. Introduction 291

2\. Reporter gene vectors and fusions 292

3\. Green fluorescent protein 293

3.1. Modifications and practical applications of GFP 294

3.2. Commercially available vectors 296

4\. Luciferases 299

4.1. Firefly luciferase 300

4.1.1. Modifications of the luc gene 300

4.1.2. Modifications to the assay 301

4.2. Renilla luciferase (R-LUC) 302

5\. Alkaline phosphatase 303

6\. Chloramphenicol acetyltransferase 304

7\. β-Galactosidase 305

8\. Concluding remarks 306

Abbreviations 307

References 307

Chapter 7. Gene transfer and gene amplification in mammalian cells

Florian M. Wurm and Martin Jordan 309

1\. Introduction on the origin of Chinese hamster ovary cells for recombinant protein production 309

2\. The DHFR/methotrexate/CHO expression system: a multi-layer selection system for high-level expression of recombinant genes 311

2.1. Gene transfer into immortalized cell lines uses an increasing number of vehicle and selection systems 311

2.2. DNA transit to the nucleus and integration into chromosomal DNA is poorly understood 312

2.3. Copy number heterogeneity in transfected cell populations 315

3\. Gene amplification is a phenomenon occurring frequently in immortalized mammalian cells 316

3.1. Chromosome segments with plasmid sequences are excised and circularized to form replicating episomes, which reintegrate into the host genome 318

3.2. CHO cells with highly amplified, chromosomally localized DNA sequences are the result of long-term exposure to incrementally increased MTX concentrations 322

3.3. MTX in culture media affects the copy number of amplified sequences within a cell population 323

3.4. Unique patterns of chromosomally integrated amplified sequences in clonal recombinant cell lines 326

3.5. MTX induces heterogeneity of amplified sequences 327

3.6. Genetic instability in immortalized mammalian cells containing amplified DNA sequences is a complex, but solvable problem 329

4\. Concluding remarks 330

Abbreviations 332

References 333

Chapter 8. Co-transfer of multiple plasmids/viruses as an attractive method to introduce several genes in mammalian cells

Martin Jordan and Florian M. Wurm 337

1\. Introduction 337

2\. Multiplicity of infection (MOI) and multiplicity of transfection (MOT) 337

3\. Random distribution of vector units 339

4\. Several copies of one gene 340

4.1. Frequency of positive cells 340

4.2. Detection limits of positive cells 341

4.3. Distribution is important for interpretation 342

5\. Co-transfer of multiple genes 343

5.1. Production of stable cell lines 344

5.2. Applications for transient systems 344

6\. Conclusion 346

Abbreviations 347

References 347

Chapter 9. Optimization of plasmid backbone for gene expression in mammalian cells

Pascal Bigey, Marie Carrière and Daniel Scherman

1\. Introduction 349

2\. Bacterial DNA sequences 349

2.1. Undesirable effects in gene therapy: immune response and toxicity 350

2.1.1. Immune response 350

2.1.2. Toxicity 351

2.2. Vaccination 351

3\. Safety 351

4\. Plasmid size 351

5\. Optimization of plasmids for nuclear localization 352

5.1. Nuclear import mediated by viral DNA sequences 352

5.2. Nuclear import mediated by mammalian DNA sequences 352

5.3. Nuclear import mediated by peptide sequences 353

5.4. Nuclear import mediated by steroids 353

6\. Examples of vectors: pCOR and minicircles 354

6.1. pCOR: A plasmid with a conditional origin of replication 354

6.2. Minicircles 354

7\. Conclusions 355

Abbreviations 356

References 356

Chapter 10. Use of scaffold/matrix-attachment regions for protein production

Pierre-Alain Girod and Nicolas Mermod 359

1\. Introduction 359

2\. Chromatin structure and control of gene expression 360

2.1. MARs and loop domain organization 360

2.2. MAR-mediated transcriptional regulation 362

2.2.1. The One gene-One MAR hypothesis 362

2.2.2. MARs as regulatory switches 363

2.3. DNA sequence features of MARs 364

2.3.1. Structural motifs 364

2.3.2. MAR functional elements 364

2.4. MAR mode of action 366

2.4.1. Chromatin acetylation and accessibility 366

2.4.2. MAR sequences and chromatin dynamics 366

2.4.3. MARs as entry sites for chromatin remodelling activities 367

2.5. MAR-associated chromatin remodelling network 367

3\. Use of MAR elements for protein production 370

3.1. Copy number dependence of transgene expression 370

3.2. Use of MAR elements to increase protein production by CHO cell lines 371

3.3. MAR elements and copy number-dependent expression of the transgene 372

3.4. The effect of MAR elements on transgene expression level and stability 374

4\. Conclusion 376

Abbreviations 376

References 377

Chapter 11. Chromatin insulators and position effects

David W. Emery, Mari Aker and George Stamatoyannopoulos 381

1\. Introduction 381

2\. Chromosomal position effects 382

2.1. Random integration and silencing 382

2.2. Chromatin structure 383

2.3. Manifestation of position effects 384

2.4. Issues of experimental design 385

2.5. Sources for silencing position effects 386

3\. Chromatin insulators 387

3.1. Insulator activities 387

3.2. Topological considerations 389

3.3. Mechanisms of action 389

4\. Specific uses of chromatin insulators 390

4.1. Preventing silencing in transgenic animals 390

4.2. Preventing silencing of oncoretrovirus vectors 391

4.3. Improving gene regulation 393

Abbreviations 393

References 394

Chapter 12. Locus Control Regions

Xiangdong Fang, Kenneth R. Peterson, Qiliang Li and George Stamatoyannopoulos 397

1\. Introduction 397

2\. The β-globin locus LCR 398

3\. Properties of LCRs 401

3.1. Enhancer activity 401

3.2. Copy number-dependent gene expression 402

3.3. Timing and origin of DNA replication 402

3.4. Histone modification 403

4\. LCR knockout mice 403

5\. Mechanisms of globin gene activation by the LCR 404

6\. LCRs of other genes 405

Abbreviations 406

References 406

Chapter 13. Protein synthesis, folding, modification, and secretion in mammalian cells

Stacey M. Arnold and Randal J. Kaufman 411

1\. Introduction 411

2\. Modification of proteins in the early secretory pathway 412

2.1. Translocation 412

2.2. Asparagine-linked glycosylation 412

2.3. ER chaperones 415

2.4. The CNX/CRT cycle 416

2.5. ER-resident proteins 417

2.6. Gamma-carboxylation of glutamic acid residues 417

2.7. Beta-hydroxylation of amino acids: lysine, proline, aspartic acid, and asparagine 417

3\. Golgi modifications 418

3.1. Golgi glycosylation events 418

3.2. Tyrosine sulfation 418

3.3. Proteolytic processing 419

4\. Quality control 421

4.1. ER retention 421

4.2. Retrieval of proteins from downstream organelles 421

4.3. Rerouting from Golgi to the endosome 423

4.4. ER-Associated degradation 423

5\. Transport of proteins through the secretory pathway 424

6\. Conclusion 428

Abbreviations 428

References 429

Chapter 14. Pathways and functions of mammalian protein glycosylation

Dale A. Cumming 433

1\. Introduction 433

2\. Glycosylation of asparagine residues: N-glycosylation 434

2.1. Characteristics of N-linked glycosylation 434

2.1.1. Types of N-linked glycans 434

2.2. Assembly of the lipid-linked precursor 434

2.3. Transfer of precursor to polypeptide backbone 436

2.4. Processing of N-linked glycans 437

3\. Glycosylation of serine/threonine residues: O-glycosylation 440

3.1. The \`\`mucin type\'\' of O-glycans: GalNAc substitution of Ser/Thr 441

3.2. Xylose substitution of Ser/Thr 441

3.3. O-fucosylation/glucosylation 444

3.4. O-GlcNAc substitution of cytosolic/nuclear proteins 444

4\. Glycosyl phosphatidyl inositol (GPI)-anchored proteins 444

4.1. Structural classes of eukaryotic GPIs 445

4.2. Biosynthesis of GPIs 445

5\. What specifies glycan structure? 447

5.1. The polypeptide chain 447

5.2. The glycosylation phenotype of the cell 448

5.3. Environmental effects 449

6\. Functions of protein-linked glycans 449

6.1. Evolutionary considerations 451

Abbreviations 452

References 453

Chapter 15. Metabolic engineering of mammalian cells for higher protein yield

Hitto Kaufmann and Martin Fussenegger 457

1\. Therapeutic protein production from mammalian cells 457

2\. Initial metabolic engineering approaches 458

3\. Transcriptional hotspot targeting, chromosomal locus amplification and episomal expression strategies 458

4\. Biphasic production processes--controlled proliferation in biotechnology 459

4.1. The concept 459

4.2. Separating the phases: regulated gene expression in mammalian cells 460

4.3. Proliferation control of mammalian cells by overexpression of growth inhibitory proteins 461

5\. Counteracting suicidal tendencies: preventing cell death in mammalian cell cultures 463

6\. Third generation metabolic engineering--multiregulated multigene metabolic engineering 465

7\. Outlook 466

Abbreviations 467

References 467

Chapter 16. Translational regulation in mammalian cells

Marilyn Kozak 471

1\. Introduction 471

2\. Overview of the initiation phase of translation in eukaryotes 471

2.1. Initiation factors 472

2.2. Selection of translational start sites 473

3\. Regulation of initiation via mRNA structure 476

3.1. Context-dependent leaky scanning 476

3.2. Modulation of translation via small upstream open reading frames 478

3.3. Effects of mRNA secondary structure 481

4\. Regulation via initiation factors 481

5\. Regulation of initiation via mRNA-specific binding proteins 484

6\. Regulation of translation subsequent to the initiation step 486

7\. Complicated issues and closing notes 487

7.1. Regulation via 3\' UTR sequences 487

7.2. Internal initiation as an alternative to scanning 488

7.3. Some unanswered questions 489

Abbreviations 491

References 491

Chapter 17. Pathways of mammalian messenger RNA degradation

Angela Inácio and Stephen A. Liebhaber 495

1\. Summary 495

2\. mRNA decay comprises a major control in gene expression 495

3\. General pathways of mRNA decay 496

3.1. The closed loop model 496

3.2. 3′ Terminal deadenylation as a rate-limiting step in mRNA decay 497

3.3. 5′ Terminal decapping 498

3.4. 3′→5′ exosome-mediated decay of mammalian mRNAs 499

4\. Regulation of mRNA decay by rate-limiting endonuclease cleavage 499

5\. Decay pathways involved in mRNA surveillance 500

5.1. Nonsense-mediated mRNA decay 500

5.2. Other surveillance pathways 503

6\. Examples of decay pathways controlled by defined *cis-trans* interactions 504

6.1. Cell cycle control of mRNA stability 504

6.2. Destabilization of mRNAs by the 3\' AU-rich element 504

6.3. Control of mRNA stability in response to intracellular iron concentration 505

6.4. Determinants of highly stable mRNAs 507

6.5. Coding region stability determinants 508

6.6. Triggering mRNA destabilization by its protein product 508

7\. The role of translation in mRNA decay pathways 509

8\. Degradation of mRNA by external factors 509

9\. Conclusions 510

Abbreviations 510

References 511

Chapter 18. Pathways of mammalian protein degradation

William A. Dunn, Jr. 513

1\. Introduction 513

2\. Pathways of selective proteolysis 513

2.1. Calpain-mediated proteolysis 514

2.1.1. Calpain structure 514

2.1.2. Substrates and recognition 514

2.1.3. Regulation and inhibitors 514

2.2. Caspase-mediated proteolysis 515

2.2.1. Caspase structure 515

2.2.2. Substrates and recognition 515

2.2.3. Regulation and inhibitors 515

2.3. Ubiquitin-mediated proteasome pathway 517

2.3.1. Protein ubiquitination 517

2.3.2. Proteasome 520

2.3.3. Substrates and recognition 520

2.3.4. Regulation and inhibitors 521

2.4. Chaperone-mediated autophagy 523

2.4.1. Molecular events 523

2.4.2. Substrates and recognition 524

2.4.3. Regulation 524

3\. Pathways of nonselective proteolysis 524

3.1. Microautophagy 525

3.1.1. Molecular events 525

3.1.2. Regulation 525

3.2. Macroautophagy 525

3.2.1. Molecular events 525

3.2.2. Regulation 529

4\. Summary 531

Abbreviations 531

References 532

Chapter 19. Stabilization of proteasomal substrates by viral repeats

Nico P. Dantuma and Maria G. Masucci

1\. Introduction 535

2\. The ubiquitin--proteasome system 535

3\. Viral repeats that block proteasomal degradation 537

3.1. Epstein-Barr virus nuclear antigen (EBNA)-1 537

3.2. Identification of a repetitive sequence that blocks degradation 537

3.3. *Cis*-stabilization of cellular proteins by the GAr 538

3.4. Related viral repeats 540

3.5. Structural constraints 540

3.5.1. Length of the repeat 540

3.5.2. Composition of the repeat insert 542

3.5.3. Location of the repeat insertion 542

3.6. Mode of action 543

4\. Possible applications in gene transfer settings 544

4.1. Avoiding immune recognition 545

4.2. Stabilizing proteasome substrates 546

5\. Concluding remarks 547

Abbreviations 547

References 547

Chapter 20. Architecture and utilization of highly expressed genomic sites

Jürgen Bode, Sandra Götze, Ellen Ernst, Yves Hüsemann, Alexandra Baer, Jost Seibler and Christian Mielke 551

1\. Introduction 551

2\. Chromatin domains and transgene integration targets 551

2.1. Transcriptional functions of S/MARs 552

2.2. Silencing phenomena are counteracted by nuclear matrix association 554

2.3. The augmentation phenomenon: S/MAR actions are context-dependent 556

3\. Comparison between gene transfer by transfection and retroviral infection 558

3.1. Genomic sites targeted by transfection, electroporation and retroviral infection are distinct 559

4\. Re-use of established highly expressed genomic sites 563

4.1. Recombinase-mediated cassette exchange (RMCE) 565

4.1.1. Twin sites: excision does not exclude subsequent integration 568

4.1.2. RMCE multiplexing 569

5\. Lessons 569

Abbreviations 570

References 571

Chapter 21. Intracellular targeting of antibodies in mammalian cells

Quan Zhu and Wayne A. Marasco

1\. Introduction 573

2\. Concept of intrabodies and their mechanism of action 573

3\. Critical parameters for a successful sFv intrabody 575

4\. The source and selection of sFv antibody for intrabody construction 576

4.1. Source of sFv antibody fragment for intrabody construction 576

4.2. The selection of sFv antibody for intrabody construction 576

4.2.1. Selection by phage display 577

4.2.2. Selection by *in vitro* display 578

4.2.3. Selection by intracellular expression 578

5\. Recent applications 579

5.1. Intrabodies in AIDS research 580

5.2. Intrabodies in cancer research 581

5.3. Intrabodies in neurodegenerative disease research 582

5.4. Intrabodies in transplantation 583

6\. Future perspectives 584

Abbreviations 585

References 585

Chapter 22. Inducible gene expression in mammalian cells

Wilfried Weber and Martin Fussenegger 589

1\. Introduction 589

2\. Artificial transcription control systems 590

2.1. Dimerizing technology 590

2.1.1. Inducible dimerization systems 590

2.1.2. Repressible dimerization technology 590

2.1.3. Controlled release technology 591

2.2. Antibiotic-responsive systems 592

2.2.1. Tetracycline-responsive gene expression 592

2.2.2. Streptogramin-responsive gene expression (PIP systems) 593

2.2.3. Erythromycin-responsive gene expression 594

2.3. Receptor-based systems 595

2.3.1. Hormone receptor-modulated systems 595

2.3.2. Synthetic steroid-responsive expression 596

3\. Generic strategies to improve key characteristics of basic gene regulation systems 597

4\. Complex regulation systems 598

4.1. Combining regulatory elements for superior performance 598

4.1.1. Enhanced regulation characteristics 599

4.1.2. Rheostat vs. ON/OFF switch 599

4.2. Interconnected regulation systems 599

4.2.1. Multiple regulation technology 600

4.2.2. Artificial regulatory networks 601

5\. Conclusions 602

Abbreviations 602

References 603

Chapter 23. Protein production by large-scale mammalian cell culture

Liangzhi Xie, Weichang Zhou and David Robinson 605

1\. Introduction 605

2\. Cell Lines 606

2.1. Commonly used cell lines in industry 606

2.2. Cell banking systems 606

2.3. Cell substrate characterization 606

3\. Cell culture media and raw materials 607

3.1. Serum-free and protein-free media 607

3.2. pH control reagents 607

3.3. Release testing of culture media and raw materials 608

3.4. Prevention of microbial and viral contamination 608

4\. Cell expansion process 609

4.1. Process reproducibility 609

4.2. Operational complexity 610

4.3. Cell passaging scheme 611

5\. Cell culture process development and optimization 611

5.1. Process development 611

5.2. Process optimization strategies 612

6\. Large scale cell culture process choices 612

6.1. Batch culture 612

6.2. Fed-batch culture 612

6.3. Continuous culture 614

6.4. Perfusion culture 614

7\. Process scale-up challenges 615

7.1. Mixing 615

7.2. Oxygenation 616

7.3. Carbon dioxide accumulation 616

8\. Large scale bioreactor design 617

8.1. Choices of culture device 617

8.2. Large scale stirred-tank bioreactor design 618

8.2.1. Aspect ratio 618

8.2.2. Impellers and baffles 619

8.2.3. Sparger design 619

9\. Process validation 619

10\. Conclusion 620

Abbreviations 620

References 621

Chapter 24. Protein production in transgenic animals

Yann Echelard and Harry M. Meade 625

1\. Introduction 625

2\. Production of recombinant proteins in the milk of transgenic animals 626

2.1. General overview 626

2.2. Production species 626

2.2.1. Mice 627

2.2.2. Rabbits 629

2.2.3. Pigs 629

2.2.4. Sheep 629

2.2.5. Goats 630

2.2.6. Cows 630

2.3. Engineering of mammary gland-specific transgenes 631

2.4. Generation of transgenic animals 632

2.4.1. Pronuclear microinjection 632

2.4.2. Somatic cell nuclear transfer 632

2.4.3. Transient approaches 633

2.5. Protein purification from the milk of transgenic animals 634

3\. Other transgenic bioreactors 634

3.1. Production of recombinant proteins in the blood of transgenic animals 634

3.2. Transgenic chickens 635

3.3. Bladder-specific expression 636

3.4. Seminal vesicle 636

4\. Conclusions 637

References 637

Chapter 25. Strategies for the purification of recombinant proteins

Steven L. Giardina 641

1\. Introduction 641

2\. Developing a rational approach for protein purification 641

3\. Assay development 642

3.1. Evaluation of product purity and identity 642

4\. Product recovery and initial purification 643

5\. Purification of proteins from culture media 644

6\. Purification of proteins from cell lysates 644

7\. Volume reduction and partial purification 645

8\. Chromatographic purification of recombinant proteins 649

8.1. Affinity chromatography 649

8.1.1. Affinity chromatography of fusion proteins 650

8.2. High-resolution chromatography 651

8.3. Hydrophobic interaction chromatography 652

8.4. Ion-exchange chromatography 653

8.5. Size-exclusion chromatography 656

9\. Product stability and long-term storage 657

Abbreviations 658

References 658

Index 661
